Key Highlights

  • Four signed deals and one reported negotiation lifted five mid-cap stocks by 35.74% to 93.03% over one month in published market data as of October 28, 2026: Braze, Surgery Partners, DXC Technology, RXO and Option Care Health.
  • Offer prices are USD 47.50 per share for Braze, USD 23.50 for Surgery Partners, USD 30.25 for RXO and USD 32.05 for Option Care Health, with the stocks trading 0.6% to 8.3% below those levels, simple arithmetic.
  • Closings are expected in the first quarter of 2027 for Surgery Partners, in the first half of 2027 for Option Care Health and RXO, and during Salesforce's fiscal 2028, which runs from February 2027 to January 2028, for Braze (NASDAQ:BRZE).
  • DXC Technology (NYSE:DXC) is the exception: it was reported on October 19, 2026 to be in advanced talks to sell its insurance unit for about USD 2.4 billion, but no agreement has been signed.

Braze (NASDAQ:BRZE): Up 93.03% on a Salesforce Offer

Braze (NASDAQ:BRZE) rose 93.03% in a month to USD 45.83 after Salesforce agreed on October 20, 2026 to buy it for USD 47.50 in cash, about USD 5.66 billion of enterprise value. On October 20, 2026, Salesforce (NYSE:CRM) announced a definitive agreement to acquire Braze for USD 47.50 in cash per Class A share, an enterprise value of about USD 5.66 billion. J.P. Morgan advised Salesforce and Qatalyst Partners advised Braze. The USD 30.04 close on October 19 was itself far above the level a month earlier. Working back from the 93.03% one-month gain, the implied price a month ago was about USD 23.74, so the stock had already risen about 27% before the announcement, simple arithmetic on published numbers. Braze (NASDAQ:BRZE) has also gained 77.75% over three months and 33.44% year to date, and its quarterly revenue growth of 26.2% shows why a strategic buyer saw value. The main risk is that the deal fails. Published terms include a USD 300 million fee payable by Salesforce if regulators block the transaction and a USD 191 million fee payable by Braze if it accepts a superior proposal.

Surgery Partners (NASDAQ:SGRY): Up 64.70% on a USD 23.50 Buyout

Surgery Partners (NASDAQ:SGRY) rose 64.70% in a month to USD 23.36 after HealthSpan Partners agreed on October 26, 2026 to buy it for USD 23.50 per share in cash. On October 26, 2026, HealthSpan Partners, an affiliate of Bon Secours Mercy Health, announced an agreement to acquire Surgery Partners (NASDAQ:SGRY) for USD 23.50 per share in cash, a transaction worth about USD 5.7 billion. Earlier published reports had pointed to a price near USD 20 per share, so the final price came in above those talks. Surgery Partners operates about 176 surgery centers and hospitals across 30 states, according to published reports. Debt rose from USD 2.97 billion in fiscal 2022 to USD 4.04 billion in fiscal 2025, which is why the equity value is a small part of the enterprise price. Regulatory review is the main risk, because a hospital system buying a large surgery network can draw scrutiny, and a delay would keep the shares tied to the spread.

DXC Technology (NYSE:DXC): Up 52.58% on Insurance Unit Talks

DXC Technology (NYSE:DXC) rose 52.58% in a month to USD 15.96 after a report of advanced talks to sell its insurance unit for about USD 2.4 billion, with no deal signed. On October 19, 2026, published reports said DXC was in advanced talks to sell its insurance software and services unit to Eldridge Industries for about USD 2.4 billion, citing people familiar with the matter. The unit supplies policy administration systems and related software to life, wealth, property and casualty insurers. The last quarterly report, on July 30, 2026, showed earnings of USD 0.40 per share against USD 0.41 expected and USD 0.68 a year earlier, on revenue of about USD 3.0 billion, down 5%. Analysts are cautious: published ratings are mostly Hold with an average target near USD 12.21, well below the USD 15.96 price. DXC Technology (NYSE:DXC) has gained 41.49% over three months and 10.14% over one week, yet only 8.06% year to date, so the month is a recovery from a low base of about USD 10.46, simple arithmetic. Talks can collapse, a sale could be repriced and the remaining business would be smaller after years of falling revenue.

RXO (NYSE:RXO): Up 41.65% on a C.H. Robinson Deal

RXO (NYSE:RXO) rose 41.65% in a month to USD 27.75 after C.H. Robinson agreed to buy it for USD 30.25 per share, though the shares fell 4.64% on October 28 with the buyer's stock. On October 5, 2026, C.H. Robinson agreed to acquire RXO (NYSE:RXO) at USD 30.25 per share, a 29% premium to the October 2 close, with holders able to elect cash, stock or a mix, subject to proration, for roughly 57% cash and 43% stock overall. The stock-linked value moved on October 28, 2026 when C.H. Robinson reported adjusted earnings of USD 1.80 per share against USD 1.75 expected and revenue of USD 5.36 billion, up 29.5%, but cash from operations fell to USD 124.1 million from USD 275.4 million. Antitrust review of two large North American brokers could delay or reshape the deal, and a further fall in C.H. Robinson shares lowers what RXO holders receive.

Option Care Health (NASDAQ:OPCH): Up 35.74% on a USD 32.05 Buyout

Option Care Health (NASDAQ:OPCH) rose 35.74% in a month to USD 31.32 after CD&R and McKesson agreed on October 5, 2026 to pay USD 32.05 per share in cash. On October 5, 2026, Option Care Health (NASDAQ:OPCH) agreed to be acquired by Clayton, Dubilier & Rice and McKesson for USD 32.05 per share in cash, an enterprise value of about USD 5.8 billion. The price is about a 37% premium to the October 5 close, which implies a close near USD 23.39, simple arithmetic. The shares rose about 32.88% on the first trading day after the announcement, and the stock has gained 35.74% over a month, from an implied price near USD 23.07. Closing needs the approval of shareholders and regulators and is expected in the first half of 2027, after which the company will stop trading on Nasdaq. If the deal fails, the premium would disappear and the stock could return toward its pre-announcement level, simple arithmetic on the offer premium.

Where Things Stand

The answer is that takeover activity explains the five gains, with spreads of 0.6% to 8.3% reflecting approval risk. Surgery Partners (NASDAQ:SGRY) has the tightest spread at about 0.6%. Option Care Health (NASDAQ:OPCH) trades about 2.3% below its offer. Braze (NASDAQ:BRZE) trades about 3.5% below. RXO (NYSE:RXO) is the widest at about 8.3% because part of its payout is stock. DXC Technology (NYSE:DXC) still needs a signed agreement.